Marina Biotech and Girindus Group have entered into a strategic alliance under which Girindus will have exclusive rights to develop, supply and commercialize certain oligonucleotide constructs using Marina's Conformationally Restricted Nucleotide (CRN) chemistry. Marina will receive royalties from the sale of CRN-based oligonucleotide reagents as well as supply of cGMP material for Marina and its partners' preclinical, clinical and commercialization needs.
Marc Lemaitre, chief executive officer of Girindus America Inc. and Vorstand of Girindus AG, said, "This alliance with Marina is very important for Girindus as it clearly exemplifies our strategy to provide integrated services to our oligonucleotide customers. We have decided to enter into this alliance with Marina because we believe its proprietary CRN chemistry provides unique benefits to oligonucleotide constructs, and offers a new R&D tool to the field of nucleic acid based therapeutics."
"We are pleased to have entered into this strategic alliance with Girindus," said J. Michael French, president and chief executive officer of Marina Biotech. "Our mission here at Marina is to conduct basic research in the application of oligonucleotide-based therapeutics to treat human disease as well as to advance those therapeutics through preclinical and clinical development and ultimately to the market. This alliance with Girindus allows us to move the development and supply of CRN-based oligonucleotides to a team with exceptional experience and capability thus allowing us to focus on bringing novel therapeutics to patients in need."